Medios AG

ILM1

Equity

ISIN DE000A1MMCC8 / Valor 19069483

Xetra (2025-11-20)

EUR 14.00-0.85%

Medios AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Medios AG is an innovative specialty pharmaceuticals company that specializes in patient-specific medicinal products. The company focuses on providing integrated solutions and partnership intelligence to ensure optimal supply of these products. Medios AG's business model revolves around meeting the growing demand for personalized medicine in the healthcare industry.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Performance

Medios AG achieved total revenue of €626.5 million in 2020, marking a 21.2% increase over the previous year. Both the Pharmaceutical Supply and Patient-Specific Therapies segments contributed to this growth with similar double-digit gains.

Profitability Impact

Despite higher revenues, the company experienced a decline in profitability. EBITDA dropped by 20% year-on-year to €13.1 million and the Earnings Before Tax (EBT) fell by 37.4% to €8.9 million, resulting in narrower margins compared to 2019.

Strategic Initiatives

The report details significant enhancements in Medios AG’s growth strategy, including targeted acquisitions like Cranach Pharma GmbH and Kölsche Blister GmbH, the expansion of its specialized pharmacy network from 200 to over 500 locations, and capital measures such as a syndicated loan and a successful capital increase.

Market Position and Share Price

Strengthening its market position, Medios AG saw its share price appreciate by approximately 42%, an impressive outperformance relative to the broader German stock market. The company also gained admission to the SDAX index, underscoring investor confidence.

Summarized from source with an LLMView Source

Key figures

1.16%1Y

-17.6%3Y

-53.5%5Y

Performance

42.4%1Y

39.5%3Y

39.5%5Y

Volatility